|Written by Rob Goldman|
With a recent prediction suggesting that Hillary Clinton has an 88% chance of winning the Presidential election we thought it was time to give you our #1 Hillary Clinton stock pick for the year.
APPLY TO AFFECTED AREA
Statistically speaking the major indices hit new highs last week. Considering they barely budged from a week earlier and earnings season is basically over, color me unimpressed.
If ever there was a time for stocks to start a mini-fall it is now. Let’s start with the VIX. According to this weekend’s edition of Barron’s. a boatload of calls have been purchased in recent days on the CBOE Volatility Index, or the VIX. That means a lot of money is being wagered on a market fall. And these late September calls, not something further out.
Look, a bet on the VIX year-to-date might be one of the worst investments of the year. VelocityShares Daily 2x VIX St ETN (NYSE—TVIX—$22.63), our fave play on the VIX just underwent a reverse split and that may stem the bleeding. Still, on a YTD basis, the damn thing is down over 82% and recently hit a 2-year low.
Conventional wisdom might say that it is going lower. The reality is that at current levels (VIX—$11.55) the index is well below its $19 average. Moreover, chartists will tell you that when it is at an excruciating low level, it tends to make a big swing to the upside which coincides with a drop in the market. Conversely, a big jump usually means stocks are now attractive. When you are sick you apply Vicks for healing. Now, you should apply VIX calls or buy TVIX to do the same in order to stave off market declines.
The Stock Market Today
It is almost like joke. Most of the indices above are up between 20-30% from their lows just six months ago. Tell me that does not give you pause. It just feels like we gotta go down before we go up, and we can go up big.
According to Factset, the current trailing 12-month P/E on the S&P 500 Index of 19.5x is the highest since 2010 when it hit 22.5x on 2/10/10. It is also currently above the 5-year, 10-year, and 15-year averages. That is a major negative, right? You tell me.
The market rose by 25% from that point until year-end. So is this all nonsense? Not at all. You can’t look at numbers at face value or history without context. That year, the EPS on the S&P 500 Index jumped by 40% in 2010 compared with 2009, so of course the index went bananas.
The difference is that right now, we will be lucky to eke out a tiny bit of growth over 2015 which is a year that saw a paltry 1.3% move in the index. So, it is a scary event. Truth be told, the same index enjoyed a 15% EPS growth rate from 2010 to 2011 yet the index only rose by 2%, due in part to high valuations.
The bottom line? Expect declines followed by a strong 4Q16 with a return to EPS growth for the first time in ages, and a 13% EPS growth rate in 2017, the highest in 6 years.
Great info, insights, and hard-hitting stories make up this week’s Say What? feature...
The New York Post
For those of you that invest in any funds, aside from ETFs, the smaller, the better.
A good sign?.
The New York Times
I guess we should not be surprised.
Florida residents, this is for you.
Conspiracy theorists, unite!
AAII Sentiment Survey (figures rounded)
WTF? Basically no change in the AAII survey but big changes in the Ticker Sense poll?This time I am following the retail guys. Bulls are on the move again and correction camp is on the exit ramp, according to Investors Intelligence. Makes no sense to my behind.
We continue to see equity outflows at a slow but steady pace. At some point the numbers will change and I believe that will come with a re-valuation and a desire by foreign investors to own U.S. assets.
The # 1 Hillary Clinton Stock
I saw a “prediction machine” figure the other day that stated Hillary Clinton has an 88% chance of winning the 2016 Presidential Election. Barring any surprises, Donald Trump seems destined to lose. That got me thinking. If there was one stock I had to buy that could be a direct beneficiary of a Clinton presidency it is Teva Pharmaceutical (NASDAQ—TEVA—$53.86—NR).
I have a long history with this stock. It was the first one I ever covered as an analyst and it was a monster winner even back then. I also believe I took them on one of their first non-deal roadshows in the U.S. Back then, the stock had a market cap of several hundred million. Today, it is $49 billion. To put it in perspective, if you bought $1000 worth of stock when I initiated coverage, it would be worth over $28,000 today. Anyway...here is the 411 on Teva.
Teva is the global leader in the production and sale of generics, bar none. For 25 years they have grown via M&A, most recently the $45B acquisition of Allergan’s generics business. The Company also produces its own specialty branded products in the central nervous system arena (Copaxone for MS is a multi-billion dollar in sales drug, as an example) along with respiratory treatment products, cancer, women’s health, and others.
The big picture for Teva as it relates to Queen Hillary is that there is nothing the Democrats (and especially Hill) like to do more than rail against high drug prices. That fits perfectly with the core Teva generics business which is the antithesis of the high priced drug market, even though they do sell some high ticket branded names.
On an investment level, the stock is trading around 10x this year’s EPS and less than 9x next year’s EPS despite the expected 15% growth rate. (How about a stock trading below its EPS growth rate for a change?) The Company has a 25% operating margin and grows revenue and EPS by the mid-teens, yet it is down 17% YTD. At 2.5 sales and 10x EPS the stock is too cheap and could jump 35% or more in a year, and once it makes a move could sustain a rise on technicals alone.
Since we are going down memory lane, Gene Marcial of Forbes (formerly BusinessWeek) did a piece recently on Teva and has quoted me many time over the years.
1498 Reisterstown Road, Suite 286 Baltimore Maryland 21208 Phone: 410.609.7100
[email protected] www.goldmanresearch.com
Launched in May 2010, The Goldman Guide is a free weekly publication of Goldman Small Cap Research and is written by Founder Rob Goldman with contributions from the GSCR contributor team. This non-sponsored investment newsletter seeks to provide investors with market, economic, political and equity-specific insights via an action-oriented, straight to the point approach. No companies mentioned in this newsletter are current sponsored research clients of the Company or its parent, unless noted, With some exceptions, all companies or investment ideas mentioned in this publication are publicly traded stocks listed either on the NYSE or the NASDAQ. Goldman Small Cap Research members and contributors’ bios, certifications, and experience can be found on our website: www.goldmanresearch.com
This newsletter was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces non-sponsored and sponsored (paid) investment research. Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The Firm’s non-sponsored research publications category, Select Research, reflects the Firm’s internally generated stock ideas, along with economic, industry and market outlooks. In virtually all cases, stocks mentioned in Select Research offerings are listed on the NYSE or the NASDAQ. Publications in this category include the weekly newsletter The Goldman Guide, Market Monitor blogs, Special Reports, and premium products such as The 30-30 Report. Goldman Small Cap Research analysts are neither long nor short stocks mentioned in this newsletter.
Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in company-specific Opportunity Research reports, updates and articles.
Goldman Small Cap Research has not been compensated for any content in this issue.
All information contained in this newsletter and in our reports were provided by the companies mentioned via news releases, filings, and their websites or generated from our own due diligence. Economic, market data and charts are provided by a variety of sources and are cited upon publication. Stock performance data and information are derived from Yahoo! Finance and other websites or sources, as noted. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, other firms, or other financial news outlets. Goldman Small Cap Research relied solely upon information provided by companies through filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, blog, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
Separate from the factual content of our articles about the company featured in this newsletter, we may from time to time include our own opinions about the companies profiled herein, their businesses, markets and opportunities. Any opinions we may offer about the companies are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.